Name | Type | Description | Interventions |
---|
GEP low TMB low: Pembrolizumab + MK-1308 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the Recommended Phase 2 Dose ([RP2D], dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP low TMB low: Pembrolizumab + MK-4280 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP low TMB low: Pembrolizumab + Lenvatinib | Experimental | Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity. | |
GEP low TMB hi: Pembrolizumab + MK-1308 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP low TMB hi: Pembrolizumab + MK-4280 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP low TMB hi: Pembrolizumab + Lenvatinib | Experimental | Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity. | |
GEP hi TMB low: Pembrolizumab + MK-1308 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP hi TMB low: Pembrolizumab + MK-4280 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP hi TMB low: Pembrolizumab + Lenvatinib | Experimental | Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity. | |
GEP hi TMB hi: Pembrolizumab + MK-1308 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-1308 at the RP2D (dose and schedule based on study NCT03179436) until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP hi TMB hi: Pembrolizumab + MK-4280 | Experimental | Participants receive pembrolizumab 200 mg Q3W plus MK-4280 200 mg or 800 mg Q3W until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). | |
GEP hi TMB hi: Pembrolizumab + Lenvatinib | Experimental | Participants receive pembrolizumab 200 mg Q3W plus lenvatinib 20 mg once daily until disease progression, or until the participant has received 35 administrations of pembrolizumab (approximately 2 years). Participants completing 35 infusions of pembrolizumab may continue with lenvatinib alone until disease progression or toxicity. | |